Floatz logo

Oxodotreotide

Metastatic Adrenal Gland Pheochromocytoma

M.D. Anderson Cancer Centerprotein_peptidePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Metastatic Adrenal Gland Pheochromocytoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
M.D. Anderson Cancer Center
Phase 2CCC
Veliparib
Vanderbilt-Ingram Cancer Center
Phase 1CC
Capecitabine
Vanderbilt-Ingram Cancer Center
Phase 1CC

Same molecule, other indications

Oxodotreotide is also rated in:

pancreatic neuroendocrine tumorDormant
BBB
Indicative ·
75 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Dormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →